Core Viewpoint - 康基医疗 (09997.HK) is proposing to privatize the company through an agreement under Section 86 of the Companies Ordinance, with Knight Bidco Limited as the offeror [1] Group 1: Privatization Proposal - The proposal involves the company becoming a wholly-owned subsidiary of Knight Bidco Limited, leading to the delisting of its shares from the Hong Kong Stock Exchange [1] - The cancellation price is set at HKD 9.25 per share, representing a premium of approximately 9.9% over the last trading price of HKD 8.42 [1] - The board will appoint an independent financial advisor to provide opinions to the independent board committee regarding the proposal [1] Group 2: Financial and Operational Context - The company faces challenges in raising funds from the equity market due to ongoing pressure on transaction prices and limited liquidity of its shares [1] - Considering the costs associated with being listed, the company believes that maintaining its listing status offers limited benefits [1] - Implementing the privatization proposal is expected to alleviate short-term financial performance pressures and allow the company to focus on strategic goals requiring additional resource allocation for sustainable future growth [1] Group 3: Trading Resumption - The company has applied for the resumption of trading of its shares on the Hong Kong Stock Exchange starting from 9:00 AM on August 13, 2025 [1]
康基医疗(09997.HK)建议以协议安排方式私有化及撤销公司上市地位 8月13日复牌